The slip
PARKINSON RECEIPTno. 5352
21 Oct 2026, 13:23 UTCdopamine neurons, braak
predictionOPA3 in dopamine neurons tracks Braak Lewy-body stage
registeredf029abcea81226f1
discovery+0.30 p=0.428 n=9
replication-0.74 p=0.021 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.30, p 0.428)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTc7ce230485565e1308c1facf…
follows d067ed1e5d2f…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 5352: OPA3 in dopamine neurons, braak
- power
- full sample -0.23 (p 0.355, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.460, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.14, sign flips 0; without severely affected donors -0.23 (p 0.355, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0096, n 18) vs -0.23 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OPA3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up OPA3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 3.8e-4)